Internal Server Error

Vaxess - About the company

Vaxess is a series D company based in Cambridge (United States), founded in 2011 by Michael Schrader and Kathryn Kosuda. It operates as a Developer of novel vaccine formulations using silk stabilization platform. Vaxess has raised $117M in funding from investors like RA Capital Management, Norwich Ventures and Engine. The company has 3460 active competitors, including 1128 funded and 793 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of novel vaccine formulations using a silk stabilization platform. Technology includes extracting fibroin from silk in which biological compounds are encapsulated to provide heat stability. It is also developing product formats that enable novel routes of administration like microneedles for transdermal applications. It has developed MIMIX therapies that help in treating cancers such as skin cancers, breast cancer, and infectious diseases.
Social
XFacebook
Key Metrics
Founded Year
2011
Location
Cambridge, United States
Stage
Series D
Total Funding
$117M in 30 rounds
Latest Funding Round
Ranked
Employee Count
129 as on Sep 30, 2026
Similar Companies
Sign up to download Vaxess' company profile

Vaxess's funding and investors

Vaxess has raised a total funding of $117M over 30 rounds. Its first funding round was on Apr 25, 2012. Vaxess has 18 institutional investors.

Here is the list of recent funding rounds of Vaxess:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Aug 27, 2025
2070214
Series D
2363339
9383942
1481051
3888986
Feb 14, 2025
2987672
Series D
3021188
6947433
1998185
Sep 16, 2024
4771549
Grant (prize money)
5536474
9555843
9595833
lockAccess funding benchmarks and valuations. Sign up today!

Vaxess' founders and board of directors

Founder? Claim Profile
The founders of Vaxess are Michael Schrader and Kathryn Kosuda.
Here are the details of Vaxess' key team members:

Vaxess' employee count trend

Vaxess has 129 employees as of Sep 26. Here is Vaxess's employee count trend over the years:
Employee count trend for Vaxess
lockUncover Vaxess' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Vaxess's Competitors and alternates

Top competitors of Vaxess include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Vaxess, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Jazz Pharmaceuticals
Jazz Pharmaceuticals
2003, Dublin (Ireland), Public
Developer of novel biopharmaceutical medicines for unmet medical needs
$265M
82/100
2nd
Logo for BeiGene
BeiGene
2010, Cambridge (United States), Public
Developer of targeted and immune-oncology drugs against cancer
$172M
77/100
3rd
Logo for Kite Pharma
Kite Pharma
2009, Los Angeles (United States), Acquired
Developer of cancer immunotherapy products using genetic engineering
$97.7M
76/100
4th
Logo for Attovia
Attovia
2023, Fremont (United States), Public
Developer of antibody-based therapeutics for immune-mediated diseases and oncology
$255M
72/100
5th
Logo for Erasca
Erasca
2018, San Diego (United States), Public
Developer of small molecule based therapeutics for cancer
$300M
72/100
6th
Logo for Tango Therapeutics
Tango Therapeutics
2017, Cambridge (United States), Public
Developer of drugs for the treatment of cancer
$165M
72/100
7th
Logo for Elicio
Elicio
2012, Cambridge (United States), Public
Developer of vaccines for treating cancer
$47.4M
72/100
8th
Logo for Relay Therapeutics
Relay Therapeutics
2016, Cambridge (United States), Public
Developer of drug discovery platform and study protein motion
$520M
71/100
9th
Logo for Immuneel
Immuneel
2018, Bengaluru (India), Series B
Developer of T-cell therapies for the treatment of cancer
$49.8M
71/100
10th
Logo for BioNTech
BioNTech
2008, Mainz (Germany), Public
Developer of immunotherapeutics for the treatment of cancer and other diseases
$861M
71/100
39th
Logo for Vaxess
Vaxess
2011, Cambridge (United States), Series D
Developer of novel vaccine formulations using silk stabilization platform
$117M
67/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Vaxess's competitors? Click here to see the top ones

Vaxess's Investments and acquisitions

Vaxess has made no investments or acquisitions yet.

Reports related to Vaxess

Here is the latest report on Vaxess's sector:

News related to Vaxess

lockFilter this list
Media has covered Vaxess for a total of 2 events in the last 1 year, 1 of them has been about company updates.
•
Startup developing vaccines-in-a-patch gets new CEOThe Business Journals•May 23, 2024•Vaxess
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Vaxess

Explore our recently published companies
  • VEINLAND - Seddiner See based, 2006 founded, Unfunded company
  • Vantec - Webster City based, 1983 founded, Acquired company
  • Unique Instruments - Bengaluru based, 1995 founded, Funding Raised company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford